Desperately seeking serotonin… A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders
PJ Pasricha - Gastroenterology, 2007 - gastrojournal.org
In March 2007, Novartis suspended marketing of tega-serod maleate (Zelnorm), an agonist
for the 5-HT4 serotonin receptor used for patients with irritable bowel syndrome (IBS) and
constipation. This event was precipitated after a routine safety review of the drug by Swiss
regulators in which 29 studies involving 11,000 patients were pooled and analyzed: 13
patients on tegaserod experienced ischemic cardiovascular events (including 1 death) as
compared with only 1 subject on placebo. Shortly after this was brought to its attention, the …
for the 5-HT4 serotonin receptor used for patients with irritable bowel syndrome (IBS) and
constipation. This event was precipitated after a routine safety review of the drug by Swiss
regulators in which 29 studies involving 11,000 patients were pooled and analyzed: 13
patients on tegaserod experienced ischemic cardiovascular events (including 1 death) as
compared with only 1 subject on placebo. Shortly after this was brought to its attention, the …
以上显示的是最相近的搜索结果。 查看全部搜索结果